About Open Monoclonal Technology
Open Monoclonal Technology is a company based in Palo Alto (United States) founded in 2007, and was acquired by Ligand Pharmaceuticals in December 2015. Monoclonal antibody technologies are developed for biotech applications.
Company details
Open Monoclonal Technology was founded in 2007 and is headquartered in Palo Alto, United States. The biotechnology sector is addressed through the creation and licensing of monoclonal antibody platforms. Antibody discovery and production services are offered to support research in immunology and therapeutics. Operations are managed via the domain openmonoclonaltechnology.com, with a focus on accessible technology solutions in the field.
- Headquarters Palo Alto, United States
- Stage Acquired
- Website openmonoclonaltechnology.com
- Acquired by Ligand Pharmaceuticals (Dec 2015)
- Investors
- Acquired byLigand Pharmaceuticals
(Dec 2015)
Investors in Open Monoclonal Technology
Open Monoclonal Technology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for Open Monoclonal Technology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Open Monoclonal Technology
2 dated milestones of Open Monoclonal Technology across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Open Monoclonal Technology is founded.
- Exit Acquired by Ligand Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Open Monoclonal Technology
Open Monoclonal Technology was founded in 2007.
Open Monoclonal Technology is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Open Monoclonal Technology was founded in 2007 and is headquartered in Palo Alto, United States. The biotechnology sector is addressed through the creation and licensing of monoclonal antibody platforms. Antibody discovery and production services are offered to support research in immunology and therapeutics. Operations are managed via the domain openmonoclonaltechnology.com, with a focus on accessible technology solutions in the field.
Open Monoclonal Technology has 1 investor. Key investors include Ligand Pharmaceuticals.
Yes. Open Monoclonal Technology was acquired by Ligand Pharmaceuticals in December 2015.